CSL Behring’s critical care therapies encompass a range of life-saving treatments, with particular emphasis in various settings.

Hereditary angioedema (HAE) is a rare, chronic, genetic disease. Left untreated, it can cause severe — even life threatening — and rapid swelling attacks as often as several times each month. CSL Behring produces a C1-INH concentrate, a plasma-derived therapy, containing the C1-INH protein that is missing or defective in patients with HAE, to help them manage the disease.

We offer Prothrombin Complex Concentrate (PCC) that helps to control bleeding arising from congenital or acquired deficiency of clotting factors II, VII, IX, and X — all of which are vital for effective blood clotting. Fibrinogen (Factor I) concentrate replaces a major protein involved in clot formation and helps control bleeding in patients with congenital fibrinogen deficiency or extensive blood loss. Factor XIII concentrate also replaces the missing or deficient factor XIII in congenital and acquired bleeding disorders.

Other products are used for coagulation disorders in the shock and trauma setting. Our antithrombin concentrate is used to treat excessive systemic coagulation arising from sepsis, trauma, or gynecological complications. Streptokinase is a thrombolytic therapy used for treatment of acute myocardial infarction to dissolve clots.

Our critical care therapies also include albumin to stabilize blood pressure in shock or sepsis patients who are albumin deficient. Albumin is also used to treat burn patients, augment fluid replacement therapy in cardiac surgery, and treat certain liver disorders. Human Serum Albumin is also used in multiple areas of therapeutic development and production as an excipient due to its presence as a natural protein in the human body.